'Mini-tumours' created to battle cancer

Image
Press Trust of India London
Last Updated : Feb 26 2018 | 12:00 PM IST
Scientists have successfully grown mini versions of patients' tumours in a lab - and tested them against dozens of drugs to find the best possible treatment.
In the study published in the journal Science, researchers treated the lab-grown 'mini tumours' with a range of drugs.
They then looked to see how this compared to how successful treatment was in those patients.
The approach found a drug that had a chance of shrinking a patient's tumour in almost nine in 10 cases.
Drugs that did not work in patients also had no effect on the mini tumours. This suggests they could help predict when drugs would not work, researchers said.
The study, led by scientists at The Institute of Cancer Research (ICR) in the UK, was carried out in bowel and stomach cancers, and other cancers of the digestive system.
The results of the study did not change how patients were treated. However, the approach could be used in the future to help choose treatment.
According to Nicola Valeri, who led the study, the technique needed to be tested in large clinical trials, but that it "has the potential to help deliver truly personalised treatment."
Mini tumours, also called organoids, are tiny balls of cancer cells grown in the lab.
They can be grown from a tissue sample (biopsy). Scientists take cells from a tumour and place them inside a gel, where they are free to grow as a 3D ball.
Researchers believe that growing the cancer cells in this way can more closely mirror how they behave inside the body.
They grew mini tumours from biopsies taken from 71 patients with advanced bowel, stomach or bile duct cancer that had spread to other parts of the body.
The researchers tested 55 cancer drugs on the mini tumours, allowing them to compare the results to how each patient's cancer responded to the treatment they were given.
Mini tumours were more effective at predicting when drugs would be effective than looking for gene faults (mutations) in the cancer cells' DNA.
The study focused on stomach and bowel cancer, but Valeri said that "the technique could be applied to a wide variety of cancer types".
Organoids have already been grown from a variety of different cancers, including liver, pancreatic and oesophageal.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 26 2018 | 12:00 PM IST

Next Story